Management of Myelofibrosis during Treatment with Ruxolitinib: A Real-World Perspective in Case of Resistance and/or Intolerance

The development and approval of ruxolitinib, the first JAK1/2 inhibitor indicated to treat myelofibrosis, has improved patient outcomes, with higher spleen and symptoms responses, improved quality of life, and overall survival. Despite this, several unmet needs remain, including the absence of resis...

সম্পূর্ণ বিবরণ

গ্রন্থ-পঞ্জীর বিবরন
প্রধান লেখক: Breccia, Massimo, Palandri, Francesca, Guglielmelli, Paola, Palumbo, Giuseppe Alberto, Malato, Alessandra, Mendicino, Francesco, Ricco, Alessandra, Sant’Antonio, Emanuela, Tiribelli, Mario, Iurlo, Alessandra
বিন্যাস: Online প্রবন্ধ পাঠ‍্য
ভাষা:English
প্রকাশিত: MDPI 2022
বিষয়গুলি:
Article
অনলাইন ব্যবহার করুন:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9325304/
https://www.ncbi.nlm.nih.gov/pubmed/35877255
http://dx.doi.org/10.3390/curroncol29070395

আন্তর্জাল

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9325304/
https://www.ncbi.nlm.nih.gov/pubmed/35877255
http://dx.doi.org/10.3390/curroncol29070395

অনুরূপ উপাদানগুলি